Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 35,697 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...
2025-11-10 5:15 PM EST
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering (the "Offering")....
2025-10-03 5:00 AM EDT
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders"....
2025-08-18 5:05 PM EDT
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees.The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such...
2025-08-11 6:05 PM EDT
Marvel Biosciences Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces that, further to its press releases of March 28, 2025 and May 2, 2025, it has closed its non-brokered private placement (the "Offering"). Pursuant to the Offering, the Company issued an aggregate of 8,150,000 units (the "Units") at a price of $0.125 per Unit for aggregate gross proceeds of...
2025-05-12 6:05 PM EDT
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the second tranche of its non-brokered private placement of up to 12,000,000 units (the "Units") at a price of $0.125 per Unit for gross proceeds of...
2025-05-02 7:00 AM EDT
Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment
Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute.The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in comparison to...
2025-04-30 7:00 AM EDT
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025.Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le...
2025-04-16 7:00 AM EDT
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conference (AAIC), taking place in July 2025.The Company will present preclinical data from its acute Alzheimer's disease study, conducted in collaboration...
2025-04-14 7:00 AM EDT
Marvel Biosciences Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, subject to approval of the TSX Venture Exchange (the "TSXV"), it has closed the first tranche of a non-brokered private placement of up to 12,000,000 units (the "Units") at a price of $0.125 per Unit for gross proceeds of up to $1,500,000 (the "Offering"). Each Unit will be...
2025-03-28 4:30 PM EDT
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-204, as a potential treatment for Rett Syndrome.This decision follows strong preclinical data showing MB-204's sustained benefits, outperforming...
2025-03-17 7:00 AM EDT
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in comparison to Trofinetide (100 mg/kg injected once daily), the only...
2025-03-13 7:00 AM EDT
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, on May 5 and 6, 2025.The Conference brings together U.S., Canadian and international investors...
2025-03-11 7:00 AM EDT
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce that the Chinese patent office has issued a notice of allowance for its lead compound MB-204. This is the first allowance worldwide for this family."We are pleased with this allowance of claims to secure key composition of matter intellectual property...
2025-01-16 7:00 AM EST
Marvel Biosciences Announces Private Placement for up to $2.5 Million
Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company (each a "Common Share") at a price of $0.15 per Common Share for gross proceeds of a minimum of $1,935,000 and up to a maximum of $2,500,000 (the "Offering").It is anticipated that the net proceeds from the Offering will be used to...
2025-01-07 7:00 AM EST
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
Calgary, Alberta--(Newsfile Corp. - November 26, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), are pleased to share additional data from its ongoing preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. Marvel also announces plans to engage with the FDA to discuss these promising pilot results.The study evaluated MB204, Marvel's lead compound, in...
2024-11-26 7:00 AM EST
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research
Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the preclinical validation of MB204 as a treatment for Alzheimer's disease. This funding represents a significant step forward for Marvel, providing the...
2024-11-21 7:00 AM EST
Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - November 7, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB204, as a potential new treatment for Rett syndrome. The study, conducted by experts at the iBraiN Institute in Tours (France), demonstrated that chronic oral dosing of MB204 restored social interaction behaviors to...
2024-11-07 7:00 AM EST
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior...
2024-10-10 9:00 AM EDT
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model (FMR1) of Fragile X syndrome (FXS). Autism and FXS are closely related, often sharing clinical symptoms (e.g., developmental delays, challenges in...
2024-08-13 9:00 AM EDT